BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 39.53% | -61.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.53% | -61.53% | |||
| Cost of Revenue | -15.05% | 35.88% | |||
| Gross Profit | 79.06% | -74.67% | |||
| SG&A Expenses | -32.34% | 3.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.25% | 14.58% | |||
| Operating Income | 2,666.20% | -101.44% | |||
| Income Before Tax | 111.03% | -390.63% | |||
| Income Tax Expenses | 7.47% | -53.78% | |||
| Earnings from Continuing Operations | 110.86% | -393.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 110.86% | -393.60% | |||
| EBIT | 2,666.20% | -101.44% | |||
| EBITDA | 3,665.49% | -101.04% | |||
| EPS Basic | 110.34% | -355.69% | |||
| Normalized Basic EPS | 428.07% | -107.69% | |||
| EPS Diluted | 110.07% | -364.51% | |||
| Normalized Diluted EPS | 414.79% | -107.99% | |||
| Average Basic Shares Outstanding | 5.05% | 14.83% | |||
| Average Diluted Shares Outstanding | 9.46% | 10.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||